Merck & Company said its Merck Sharpe Dohme unit's Zocor, a treatment for elevated cholesterol, had received approval from an advisory committee of the Food and Drug Administration. The company said Zocor, first introduced in Sweden in 1988, had 1990 sales of $290 million in more than 20 countries. Merck's stock rose $1.375 today, to $105.625, on the New York Stock Exchange.
